USFDAJun 5, 2026, 08:01 AM
BioCardia's CardiAMP Heart Failure II Trial May Support FDA PMA
AI Summary
BioCardia announced receipt of FDA minutes confirming its CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for its CardiAMP Cell Therapy System for ischemic heart failure of reduced ejection fraction (HFrEF). The FDA previously indicated a preference for two trials for approval but considers the system safe. CEO Peter Altman emphasized the patient need and the strength of existing data. Japan's PMDA also indicated that clinical results from three completed trials likely provide sufficient evidence for approval.
Key Highlights
- FDA minutes confirm CardiAMP Heart Failure II Trial may support Premarket Approval (PMA).
- PMA is the most rigorous device marketing application for high-risk medical devices.
- FDA previously indicated the CardiAMP Cell Therapy System is safe.
- CardiAMP targets ischemic heart failure of reduced ejection fraction (HFrEF).
- Japan PMDA indicated three completed trials likely support approval submission.
- Upcoming catalysts include CardiAMP HF Manuscript publication and Japan PMDA Submission in Q4 2026.
Price Impact
More from BCDA